Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Operating Leases (2019 - 2022)

Rein Therapeutics (RNTX) has disclosed Operating Leases for 4 consecutive years, with $217000.0 as the latest value for Q3 2022.

  • Quarterly Operating Leases rose 119.19% to $217000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $217000.0 through Sep 2022, up 119.19% year-over-year, with the annual reading at $69000.0 for FY2021, N/A changed from the prior year.
  • Operating Leases for Q3 2022 was $217000.0 at Rein Therapeutics, roughly flat from $217000.0 in the prior quarter.
  • The five-year high for Operating Leases was $4.9 million in Q1 2019, with the low at $69000.0 in Q4 2021.
  • Average Operating Leases over 4 years is $2.4 million, with a median of $2.2 million recorded in 2020.
  • The sharpest move saw Operating Leases tumbled 97.64% in 2021, then surged 119.19% in 2022.
  • Over 4 years, Operating Leases stood at $4.6 million in 2019, then fell by 8.5% to $4.2 million in 2020, then tumbled by 98.36% to $69000.0 in 2021, then skyrocketed by 214.49% to $217000.0 in 2022.
  • According to Business Quant data, Operating Leases over the past three periods came in at $217000.0, $217000.0, and $217000.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.